These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16883325)

  • 1. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
    Sarafidis PA; Bakris GL
    Kidney Int; 2006 Oct; 70(7):1223-33. PubMed ID: 16883325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR-γ agonism for cardiovascular and renal protection.
    Sarafidis PA; Georgianos PI; Lasaridis AN
    Cardiovasc Ther; 2011 Dec; 29(6):377-84. PubMed ID: 20840193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR-gamma-agonists' renal effects.
    Izzedine H; Launay-Vacher V; Buhaescu I; Heurtier A; Baumelou A; Deray G
    Minerva Urol Nefrol; 2005 Dec; 57(4):247-60. PubMed ID: 16247347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
    Sarafidis PA; Stafylas PC; Georgianos PI; Saratzis AN; Lasaridis AN
    Am J Kidney Dis; 2010 May; 55(5):835-47. PubMed ID: 20110146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
    Zheng F; Guan Y
    Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
    Noble J; Baerlocher MO; Silverberg J
    Can Fam Physician; 2005 May; 51(5):683-7. PubMed ID: 15934272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
    Tawfik MK
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):600-9. PubMed ID: 22774400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
    Grossman E
    J Hum Hypertens; 2003 Jan; 17(1):5-6. PubMed ID: 12571610
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can glitazones provide protection of the kidneys?].
    Bonnet F
    Journ Annu Diabetol Hotel Dieu; 2007; ():77-84. PubMed ID: 18610759
    [No Abstract]   [Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.